Frequent cannabis consumption is associated with a higher rate of mild hallucinations, unusual thoughts, and depressive symptoms compared to occasional use or abstinence. Starting cannabis at a younger age also correlates with an increase in these subclinical symptoms. The findings were published in the Journal of Psychiatric Research.
Psychotic-like experiences are phenomena that resemble the symptoms of psychotic disorders like schizophrenia but occur at a much lower intensity. They can include mild paranoia, hearing occasional whispers, or holding highly unusual beliefs. These experiences do not mean a person has a psychiatric disorder.
About seven to thirteen percent of the general population report having these mild perceptual experiences at some point. While often harmless, these subclinical symptoms can sometimes act as early warning signs for future mental health conditions.
In psychiatric terminology, symptoms fall into distinct categories. Positive symptoms refer to the addition of abnormal experiences, such as hallucinations or delusions. Negative symptoms refer to a loss of typical emotional responses, such as a lack of motivation, social withdrawal, or a flattened affect. Depressive symptoms involve persistent sadness and low energy.
Don’t miss the next big psychology finding
Every morning, PsyPost sends a short briefing on the most interesting new peer-reviewed research in psychology and neuroscience.
University of Turin psychiatrist Valerio Ricci and his colleagues noticed a gap in the existing scientific literature regarding these symptoms. Past investigations often focused exclusively on healthy community volunteers or individuals already diagnosed with severe psychotic disorders.
The researchers wanted to study people who fell somewhere in the middle. They focused on individuals receiving psychiatric care for non-psychotic issues, such as anxiety or mood disorders. This group carries some underlying mental health vulnerability but does not have schizophrenia.
The research team recruited 150 adults between the ages of 18 and 40 from psychiatric clinics in Italy. They excluded anyone with a current or past psychotic disorder. They also excluded anyone with an immediate family member who had a psychotic disorder.
Participants were divided into three groups based on their daily habits. The heavy use group consisted of 43 individuals who consumed cannabis five or more days a week. The occasional use group included 47 individuals who used cannabis one to four times a month.
The difference in consumption volume between the active user groups was massive. The heavy users consumed an average of 2.8 grams of cannabis daily. In contrast, the occasional users consumed an average of 3.2 grams over the course of an entire month.
The groups also favored different methods of consumption. The heavy users predominantly preferred smoking cannabis. The occasional users were more likely to use vaporizers.
The remaining 60 participants were a control group with no history of cannabis use. To ensure accuracy, the researchers verified the participants’ self-reported drug habits with urine toxicology screenings. They also gathered data on the participants’ use of tobacco, alcohol, and prescription medications.
The primary measurement tool was the Community Assessment of Psychic Experiences scale. Participants rated how often they experienced various positive, negative, and depressive symptoms.
To evaluate life skills, clinicians used the Global Assessment of Functioning and Clinical Global Impression rating scales. These standardized instruments evaluate a person’s overall psychological, social, and occupational well-being.
The heavy cannabis users reported substantially higher scores for positive symptoms than the other two groups. Positive symptoms in this context can include feeling as if other people are reading your mind or feeling inexplicably detached from your own body.
The heavy users also reported elevated levels of depressive symptoms. The occasional users scored lower than the heavy users in both categories but reported more symptoms than the non-users. The frequency of cannabis consumption correlated strongly with the severity of these specific experiences.
The age at which participants first started using cannabis also played a role. Individuals who began using cannabis before the age of 16.4 years showed elevated symptom scores compared to those who started later. A longer overall duration of cannabis use followed a similar pattern.
The human brain contains an endocannabinoid system, which is a network of cellular receptors involved in regulating mood, memory, and perception. During adolescence, this system undergoes rapid development and reorganization. Introducing external cannabinoids during this sensitive window might alter regular neurological development.
The researchers found no statistically significant differences among the three groups regarding negative symptoms. Avolition and emotional flatness remained relatively consistent regardless of how much cannabis a person consumed. The researchers noted that standard symptom questionnaires might not be sensitive enough to capture subtle deficits in motivation.
Daily functioning was noticeably lower in the heavy use group. These individuals scored worse on clinical assessments of overall well-being and daily living compared to the other participants. Occasional users did not show similar drops in daily functioning.
The data also revealed a specific connection between cannabis and tobacco. Heavy cannabis users who also smoked tobacco daily reported higher positive symptom scores than heavy cannabis users who used tobacco less frequently.
Tobacco smoking can accelerate the body’s absorption of tetrahydrocannabinol, or THC, the primary psychoactive compound in cannabis. Both substances activate reward pathways in the brain. Their combined use might amplify neurological signals beyond the effect of either drug alone.
While tobacco showed an interaction with cannabis use, other substances did not demonstrate the same pattern. The researchers accounted for alcohol, stimulants, and hallucinogens in their statistical models, but these substances did not independently predict the severity of the psychotic-like experiences.
The observational design of the research limits how the results can be interpreted. The investigators evaluated the participants at a single point in time. This prevents them from establishing cause and effect.
It is entirely possible that individuals experiencing mild hallucinations or depressive thoughts turn to cannabis for relief. This self-medication theory remains a valid alternative explanation for the correlation. People with underlying mental health vulnerabilities might use the drug to cope with their symptoms.
The study also relied on self-reported surveys. Participants may have misremembered the exact timeline or frequency of their past drug use. Additionally, some participants had a history of taking other prescription mental health medications, which could influence their symptom reporting.
The researchers did not measure the concentration of specific chemical compounds in the cannabis products used by the participants. High-potency cannabis products are known to carry different risks than those with lower levels of THC.
Future investigations would benefit from tracking individuals over several years to observe how these symptoms evolve. Incorporating chemical analysis of the specific cannabis strains consumed could also clarify how different botanical compounds affect the human brain.
The study, “Cannabis use patterns and psychotic-like experiences: a cross-sectional study of heavy users, occasional users, and non-users,” was authored by Valerio Ricci, Alessandro Sarni, Lorenzo Remondino, Marialuigia Barresi, Domenico De Berardis, Clara Cavallotto, Andrea Di Cesare, Vassilis Martiadis, Giovanni Martinotti, and Giuseppe Maina.